Build America’s PPE Supply Chain

The hantavirus outbreak aboard a cruise ship killed three people and sickened passengers from 23 countries. When critically ill patients arrived in hospitals, frontline providers needed one thing immediately: reliable personal protective equipment.

Hantavirus doesn’t make national headlines until it does. A single exposure can send a patient into respiratory failure within days. When that happens, nothing is abstract. Frontline providers need reliable access to high-quality masks, gowns and gloves immediately.

Even as these rare but deadly outbreaks remind us how quickly infectious threats emerge, the United States still depends heavily on foreign supply chains for the equipment that protects healthcare workers and patients.

President Trump’s May 11 Truth Social post capped a major shift. He’s calling for gloves, masks, gowns and syringes to be treated as strategic American-made essentials, not cheap imports that cost us jobs and leave our safety in someone else’s hands.

This is about more than policy talk in Washington. It’s about jobs close to home and the confidence that local hospitals are ready when disaster strikes.

Nationwide, U.S. companies already make personal protective equipment to the highest standards. U.S. manufacturers produce 4.8 billion nitrile gloves annually, with the capacity to scale to 30 billion. Mask production could meet more than 70 percent of hospital demand. Domestic N95 output already covers routine needs and can triple in a surge. Gown production has a clear path to supply nearly half of the U.S. hospital demand within a few years.

These are operating plants, American workers, and real supply chains ready to grow. The question is whether we choose to back them.

What has been missing is not capacity, it’s consistency. For too long, U.S. purchasing has chased the lowest sticker price, even when foreign subsidies, tariff evasion and forced labor artificially drive it down. That bargain hollowed out domestic production and left us exposed when public health emergencies, wildfires and hurricanes forced hospitals to stretch already-thin supplies.

The way America buys personal protective equipment is now a national security decision, a healthcare resilience strategy, and a statement about human rights. When 80 percent to 90 percent of the supply comes from a small handful of countries, we are accepting unnecessary risk.

The government has begun changing that equation with tougher trade enforcement. However, enforcement alone is not enough. To truly rebuild domestic manufacturing, demand must line up with capacity.

That means using purchasing as a strategic tool. The proposed Secure American Medical Supplies designation is a smart next step by using incentives to reward hospitals that choose U.S.-made personal protective equipment.

The price gap between imported and domestic personal protective equipment is overstated. Once you factor in shipping, tariffs, compliance and quality risks, that gap shrinks. A modest, targeted Medicare add-on — measured in cents per unit — can flip the economics, make American production fully competitive, and stabilize costs over time.

This requires precision. Trade enforcement should focus on products and countries with the worst abuses. Procurement policies should send clear, long-term demand signals. The goal is straightforward: build a system where every personal protective equipment order strengthens domestic capacity, and hometown communities see benefits in the form of new jobs and safe, well-supplied hospitals.

The hantavirus cluster that made headlines is a reminder that outbreaks don’t wait for policy debates to conclude. The May 11 directive has made this clear.

What happens next will decide whether America finally secures its medical supply chain or stays dependent on the same fragile system that can leave hospitals scrambling. The capacity is here. The tools are on the table. Now it’s a question of execution.